Ian Betteridge
Ian Betteridge is head of content for Russell Publishing, owners of European Pharmaceutical Review. A journalist for over thirty years, Ian has extensive experience in a wide range of areas from technology, pharmaceuticals and transport to consumer-facing publishing including automotive, women's lifestyle, parenting and much more.Â
Contact info
ArticleDay three preview: the Future of Bio/Pharma Analysis Virtual Summit 2026
Pharmaceutical manufacturing takes centre stage on Day three of The Future of Bio/Pharmaceutical Analysis Virtual Summit 2026 as speakers examine how digital technologies, artificial intelligence and advanced production methods are reshaping what is possible in the field.
NewsDay two in focus: navigating regulatory strategy at The Future of Bio/Pharmaceutical Analysis 2026
Day two of The Future of Bio/Pharmaceutical Analysis Virtual Summit 2026 focuses exclusively on regulatory strategy, with three panel sessions examining how compliance and quality pressures are reshaping how biopharma companies operate. From nitrosamine management to GLP-1 product quality, and from US agency dynamics to European regulatory reform, the programme addresses the practical challenges facing QA/QC professionals responsible for maintaining product safety and compliance in an increasingly complex drug development and manufacturing landscape.
NewsDay one in focus: rethinking QA/QC at The Future of Bio/Pharmaceutical Analysis 2026
The Future of Bio/Pharmaceutical Analysis Virtual Summit returns 23–25 June 2026 with an opening day dedicated entirely to quality assurance and control. Three expert-led panel sessions will address environmental monitoring modernisation, endotoxin testing transformation and contamination control optimisation—examining how QA/QC disciplines are adapting to advanced therapies, sustainability demands and evolving regulatory expectations including Annex 1 implementation.
NewsFDA approves first-in-class aldosterone synthase inhibitor for uncontrolled hypertension
The US FDA has approved Baxfendy (baxdrostat), the first aldosterone synthase inhibitor for hypertension, offering a novel mechanism for approximately 23 million US patients whose blood pressure remains uncontrolled despite multiple medications.
ArticleFrom endotoxins to AI: what to expect at The Future of Bio/Pharmaceutical Analysis 2026
The Future of Bio/Pharmaceutical Analysis Virtual Summit returns 23–25 June 2026 with nine expert-led sessions covering environmental monitoring modernisation, non-animal endotoxin testing, nitrosamine compliance, regulatory disruption and AI-enabled digital transformation across the biopharma manufacturing landscape.
NewsFDA approves Breztri as first triple-therapy inhaler for asthma
AstraZeneca’s Breztri Aerosphere has become the first fixed-dose triple-combination inhaler approved by the FDA for asthma maintenance treatment in adults and adolescents aged 12 and older, addressing unmet needs for approximately 13.5 million US patients uncontrolled on dual therapies.
OpinionReal-time Raman spectroscopy closes bioprocess control measurement gap
Manual sampling cycles leave bioreactor control decisions hours behind culture dynamics. Process Raman spectroscopy offers continuous, real-time measurement of critical parameters, enabling true closed-loop control in perfusion and continuous bioprocessing applications where measurement lag directly impacts yield and product quality.
OpinionProcess Raman spectroscopy: closing biomanufacturing’s measurement infrastructure gap
The biopharmaceutical industry has embraced Pharma 4.0 concepts, but the measurement infrastructure required to realise autonomous facilities and continuous bioprocessing remains underdeveloped. Process Raman spectroscopy offers continuous, non-destructive monitoring at frequencies aligned with cell culture dynamics, bridging the gap between control system capabilities and available data.
ArticleRaman spectroscopy market reaches $2.35bn driven by pharma
A recent market report projecting the combined NIR and Raman spectroscopy sector will reach $2.35 billion in 2026 underscores the rapid adoption of vibrational spectroscopy across biopharmaceutical manufacturing, with AI-enhanced Raman tools increasingly being deployed for real-time quality control.
- News
AI reshapes pharma recruitment, but skills gaps, culture and bias temper gains
Cultural change inside pharma needed to help attract tech talent and support a deeper adoption of AI in the industry, say recruiters at CPHI Frankfurt 2025.
NewsAI expert warns pharma industry: artificial intelligence is a competitor, not just a tool
Speaking at CPHI Frankfurt, Bruno Fabre underlined the importance of companies viewing the technology as a fundamental business capability, rather than “an afterthought”.
NewsTaiwan talks evidence-driven TCM at CPHI Frankfurt
Scientific and commercial opportunity for pharma companies looking to source, co develop and manufacture traditional Chinese medicine (TCM).
NewsAxplora talks reliability-first investments to secure API supply
The CDMO’s programme, presented at CPHI Frankfurt 2025, combines responsiveness to new demand and operational rigour without jeopardising supply.
NewsEnsera talks integrated design-to-manufacture model at CPHI Frankfurt 2025
Model offers mid market innovators and larger pharma companies tailored processes and scale capacity without compromising compliance.
ArticleKey trends and technologies in drug delivery for 2025 and beyond
This article delves into the key trends shaping drug delivery amid a surge of innovation, including advanced delivery systems and sustainability, and offers an outlook for the future of the sector.
ArticleAI-driven biomanufacturing: revolutionising production and quality in pharmaceuticals
This article explores how artificial intelligence (AI) is forming an essential pillar of staying competitive in pharmaceutical manufacturing, with its adoption ensuring greater efficiency of medicine production in this fast-evolving sector.